Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration

Shoji Hashimoto, Heita Kitajima, Tsuyoshi Arai, Yoshitaka Tamura, Takayuki Nagai, Hiroshi Morishita, Hiroto Matsuoka, Yuki Han, Seijiro Minamoto, Tomonori Hirashima, Tomoki Yamada, Yozo Kashiwa, Makoto Kameda, Seiji Yamaguchi, Kazuko Uno, Emi Nakayama, Tatsuo Shioda, Kazuyuki Yoshizaki, Sujin Kang, Tadamitsu Kishimoto, Toshio Tanaka
doi: https://doi.org/10.1101/2020.06.24.20134288
Shoji Hashimoto
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Heita Kitajima
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tsuyoshi Arai
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshitaka Tamura
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takayuki Nagai
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Morishita
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroto Matsuoka
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuki Han
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seijiro Minamoto
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomonori Hirashima
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomoki Yamada
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yozo Kashiwa
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Makoto Kameda
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seiji Yamaguchi
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuko Uno
2Louis Pasteur Center for Medical Research, Kyoto 606-8225, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emi Nakayama
3Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tatsuo Shioda
3Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuyuki Yoshizaki
4Institute of Scientific and Industry Research, Osaka University, Osaka 565-0871, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sujin Kang
5Laboratory of Immune Regulation, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadamitsu Kishimoto
5Laboratory of Immune Regulation, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshio Tanaka
1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ttanak@ra.opho.jp
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

We administered tocilizumab into 13 severe-to-critically ill patients with coronavirus disease 2019 (COVID-19) for compassionate use in combination with potential anti-viral agents in those who required an oxygen supply and showed increased laboratory inflammatory markers such as C-reactive protein (CRP) and ferritin. One injection of tocilizumab led to rapid improvements in clinical features, inflammatory findings, and oxygen supply in seven patients with severe COVID-19 and substantial amelioration in two patients who were critically ill, whereas four patients, who exhibited rapidly worsened respiratory function, required artificial ventilatory support even after tocilizumab treatment. Three of these four patients ultimately recovered from deterioration after methylprednisolone treatment. Administration of tocilizumab did not affect viral elimination nor IgG production specific for the virus. Compared with well-responding patients, rapidly-worsened patients showed a significantly higher ratio of ferritin vs. CRP. These findings suggest that tocilizumab has beneficial effects in severe-to-critically ill patients with COVID-19; however, in some cases, addition of methylprednisolone is required for disease rescue.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

This manuscript reports findings of observational research of compassionate use of tocilizumab.

Funding Statement

No funding was received for this report.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the institutional review board of Osaka Habikino Medical Center (Approved ID: 150-7).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The availability of all data were included in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted June 30, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration
Shoji Hashimoto, Heita Kitajima, Tsuyoshi Arai, Yoshitaka Tamura, Takayuki Nagai, Hiroshi Morishita, Hiroto Matsuoka, Yuki Han, Seijiro Minamoto, Tomonori Hirashima, Tomoki Yamada, Yozo Kashiwa, Makoto Kameda, Seiji Yamaguchi, Kazuko Uno, Emi Nakayama, Tatsuo Shioda, Kazuyuki Yoshizaki, Sujin Kang, Tadamitsu Kishimoto, Toshio Tanaka
medRxiv 2020.06.24.20134288; doi: https://doi.org/10.1101/2020.06.24.20134288
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration
Shoji Hashimoto, Heita Kitajima, Tsuyoshi Arai, Yoshitaka Tamura, Takayuki Nagai, Hiroshi Morishita, Hiroto Matsuoka, Yuki Han, Seijiro Minamoto, Tomonori Hirashima, Tomoki Yamada, Yozo Kashiwa, Makoto Kameda, Seiji Yamaguchi, Kazuko Uno, Emi Nakayama, Tatsuo Shioda, Kazuyuki Yoshizaki, Sujin Kang, Tadamitsu Kishimoto, Toshio Tanaka
medRxiv 2020.06.24.20134288; doi: https://doi.org/10.1101/2020.06.24.20134288

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (420)
  • Anesthesia (97)
  • Cardiovascular Medicine (896)
  • Dentistry and Oral Medicine (169)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (405)
  • Epidemiology (8764)
  • Forensic Medicine (4)
  • Gastroenterology (404)
  • Genetic and Genomic Medicine (1857)
  • Geriatric Medicine (177)
  • Health Economics (387)
  • Health Informatics (1284)
  • Health Policy (642)
  • Health Systems and Quality Improvement (490)
  • Hematology (206)
  • HIV/AIDS (392)
  • Infectious Diseases (except HIV/AIDS) (10543)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1748)
  • Nursing (102)
  • Nutrition (265)
  • Obstetrics and Gynecology (342)
  • Occupational and Environmental Health (459)
  • Oncology (962)
  • Ophthalmology (281)
  • Orthopedics (107)
  • Otolaryngology (176)
  • Pain Medicine (117)
  • Palliative Medicine (41)
  • Pathology (263)
  • Pediatrics (556)
  • Pharmacology and Therapeutics (264)
  • Primary Care Research (218)
  • Psychiatry and Clinical Psychology (1841)
  • Public and Global Health (3975)
  • Radiology and Imaging (650)
  • Rehabilitation Medicine and Physical Therapy (341)
  • Respiratory Medicine (534)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (196)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (79)